Karahalil Bensu, Hare Emine, Koç Göksel, Uslu İrem, Şentürk Kerem, Özkan Yağmur
1Toxicology Department, Faculty of Pharmacy, Gazi University Ankara, Ankara, Turkey.
Arh Hig Rada Toksikol. 2017 Dec 20;68(4):254-260. doi: 10.1515/aiht-2017-68-2994.
Treatment with statins is known all over the world. They are generally considered safe at therapeutic doses. Nevertheless, clinical trials are not enough to assess their scarce adverse effects such as idiosyncratic drug induced liver injury (DILI). Due to some conditions, such as concomitant usage (drug-drug interaction using an identical metabolising enzyme) and genetic polymorphisms, there is an increasing concern about their safety. Hepatotoxicity and rhabdomyolysis have begun to appear in published studies. Most of investigations have focused on both these adverse effects and mechanisms of drug induced toxicity. The present review has attempted to compile almost all of the existing studies on the hepatotoxicity of statins but not rhabdomyolysis. The aim of our study is to provide an overview of the studies on the statin-associated hepatotoxicity and to discuss the published studies. The researchers are of the opinion that the research on this topic is incomplete but extremely necessary.
他汀类药物的治疗在全球都广为人知。它们在治疗剂量下通常被认为是安全的。然而，临床试验不足以评估其罕见的不良反应，如特异质性药物性肝损伤（DILI）。由于一些情况，如合并用药（使用相同代谢酶的药物相互作用）和基因多态性，人们对其安全性的担忧日益增加。肝毒性和横纹肌溶解已开始出现在已发表的研究中。大多数研究都集中在这两种不良反应以及药物诱导毒性的机制上。本综述试图汇编几乎所有关于他汀类药物肝毒性而非横纹肌溶解的现有研究。我们研究的目的是概述关于他汀类药物相关肝毒性的研究，并讨论已发表的研究。研究人员认为，关于这个主题的研究并不完整，但极其必要。
